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Abstract

Objective This analysis explored the association of
treatment adherence with beliefs about medication, patient
demographic and disease characteristics and medication
types in rheumatoid arthritis (RA), psoriatic arthritis (PsA)
or ankylosing spondylitis (AS) to develop adherence
prediction models.
Methods The population was a subset from ALIGN, a
multicountry, cross-sectional, self-administered survey
study in adult patients (n=7328) with six immunemediated inflammatory diseases who were routinely
receiving systemic therapy. Instruments included Beliefs
about Medicines Questionnaire (BMQ) and 4-item Morisky
Medication Adherence Scale (MMAS-4©), which was used
to define adherence.
Results A total of 3390 rheumatological patients were
analysed (RA, n=1943; PsA, n=635; AS, n=812). Based
on the strongest significant associations, the adherence
prediction models included type of treatment, age, race (RA
and AS) or disease duration (PsA) and medication beliefs
(RA and PsA, BMQ-General Harm score; AS, BMQ-Specific
Concerns score). The models had cross-validated areas
under the receiver operating characteristic curve of 0.637
(RA), 0.641 (PsA) and 0.724 (AS). Predicted probabilities
of full adherence (MMAS-4©=4) ranged from 5% to
96%. Adherence was highest for tumour necrosis factor
inhibitors versus other treatments, older patients and those
with low treatment harm beliefs or concerns. Adherence
was higher in white patients with RA and AS and in
patients with PsA with duration of disease <9 years.
Conclusions For the first time, simple medication
adherence prediction models for patients with RA, PsA and
AS are available, which may help identify patients at high
risk of non-adherence to systemic therapies.
Trial registration number ACTRN12612000977875.

Introduction
In rheumatic diseases, adherence to therapy
is critical to achieving optimal outcomes1–3
and lowering non-pharmacy healthcare
costs.4 5 Adherence varies widely, depending
on the particular rheumatic disease, the
definition of adherence and the type of

Key messages
What is already known about this subject?
►► Adherence to therapy in patients with rheumatic dis-

eases is important for successful outcomes, highly
variable, often suboptimal and difficult to predict.

What does this study add?
►► The ALIGN study explored the association of patient

factors with adherence to medications in a population with immune-mediated inflammatory diseases,
including rheumatoid arthritis (RA), psoriatic arthritis
(PsA) and ankylosing spondylitis (AS).
►► In ALIGN, medication adherence in RA, PsA and
AS depended more on treatment beliefs than
disease-related factors.
►► Results from ALIGN showed that adherence was
predicted by current medication type, treatment
beliefs, age and race or disease duration.

How might this impact on clinical practice?
►► Simple models, developed from the ALIGN data, are

available and may help identify patients with RA, PsA
and AS at high risk of non-adherence to systemic
therapies.

treatment. Nonetheless, adherence appears
to be suboptimal; in a systematic literature
review, values for the proportion of adherent
patients ranged from 34% to 93% for rheumatoid arthritis (RA), 45% to 76% for psoriatic arthritis (PsA) and 75% for ankylosing
spondylitis (AS).6 Adherence for rheumatic and other chronic diseases is influenced by many factors, including patients’
beliefs about the necessity of treatment and
concerns about potential adverse effects.7
Beliefs about and adherence to systemic
medication depend on patient characteristics (eg, age, race and sex), disease
characteristics, treatment experience and
treatment patterns, although previous
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analyses have produced inconsistent results.8–16 Despite
evidence about factors being associated with poor or
high medication adherence in patients, identification
of patients at high risk of non-adherence remains difficult. A probabilistic adherence prediction model could
help rheumatologists identify patients with RA, PsA and
AS who are at high risk of non-adherence to systemic
therapies. Interventions that influence medication
adherence according to such a model, by addressing
modifiable factors like patients’ beliefs, could help
maximise adherence. However, little specific information is available about the association between medication adherence and patients’ beliefs regarding conventional synthetic disease-modifying antirheumatic drugs
(csDMARDs) and tumour necrosis factor inhibitors
(TNFis) in RA, PsA and AS as well as non-steroidal
anti-inflammatory drugs (NSAIDs) in AS.
The ALIGN study determined patients’ specific and
general beliefs towards medications and adherence to
selected systemic therapies in six immune-mediated
inflammatory diseases (IMIDs) and explored the association of treatment beliefs and other factors with medication adherence.16 The objective of this analysis was
to explore the association of patient characteristics and
attitudes with adherence to csDMARDs and TNFis in
the subset of ALIGN patients who had RA, PsA and AS
as well as adherence to NSAIDs in patients with AS and
to develop models that predict adherence to systemic
therapy in each of these three rheumatic IMIDs based on
the strongest significant associations.

and prior treatment and response based on investigator
opinion (complete, partial, no and inevaluable)) on a case
report form. Other assessments (eg, questionnaires) were
patient-reported. Patients’ illness perceptions were measured by using the Brief Illness Perception Questionnaire
(BIPQ) which consisted of eight questions that assessed
the cognitive and emotional aspects of illness perception
using a 0 to 10 scale.17 The BIPQ has been used in many
studies with a wide range of patient groups.18 Validation of
the BIPQ showed that it has good test–retest reliability, with
Pearson correlation coefficients ranging from 0.42 to 0.75
depending on the question and length of time between
the initial test and the retest.17 The Beliefs about Medicines Questionnaire (BMQ) using a 5-point Likert scale
(1=strongly disagree; 5=strongly agree; multiplied by a
factor of 5 for this study) was administered to assess general
(Overuse and Harm subscales) and specific (Concerns and
Necessity subscales) beliefs about medicines.19 Treatment
adherence was based on responses to the 4-item Morisky
Medication Adherence Scale (MMAS-4©),20 which was
derived from the Morisky, Green and Levine adherence
scale.20 21 Four questions were asked: (1) Do you ever forget
to take your medicine? (2) Do you ever have problems
remembering to take your medication? (3) When you feel
better, do you sometimes stop taking your medicine? and
(4) Sometimes if you feel worse when you take your medicine, do you stop taking it?, with yes=0, no=1 and a total
score range of 0 to 4. The MMAS-4© has been shown to
be a useful, reliable and valid measure of treatment adherence, with good sensitivity (0.81) and moderate specificity
(0.44).20 21

Methods
Study design and patients
ALIGN was a cross-sectional patient survey study
conducted across Europe, Canada, Latin America, the
Asia-Pacific region and the Middle East between June
2012 and October 2013.16 Patients provided consent
according to the Declaration of Helsinki. Consecutive
patient recruitment was carried out if patients agreed to
participate and met eligibility criteria.16 A total of 7328
adult patients with RA, PsA, AS, psoriasis, Crohn’s disease
or ulcerative colitis were enrolled if they were receiving
conventional and/or biological therapy as part of
routine management for their moderate to severe IMIDs,
including any csDMARD, NSAID (patients with AS only),
glucocorticoid (GC) and/or TNFi. Prior enrolment in a
registry was neither required nor an exclusion criterion.
Study assessments
Assessment methods have been previously reported in
detail.16 Investigators recorded patient demographics (eg,
age, sex and race (white/Caucasian, black, Asian, Hispanic,
other)), disease characteristics (eg, IMID diagnosis, duration of disease and symptoms since diagnosis and activity
(collected as ‘severity’) based on investigator opinion
(mild, mild to moderate, moderate, moderate to severe
and severe)) and treatment-related variables (eg, current

Statistical analysis
Treatments
Patients were grouped based on the treatments they were
receiving for RA, PsA and AS at the time of the study visit. The
following treatment categories were considered relevant
for all three IMIDs: csDMARD therapy (csDMARDs±GCs),
TNFi monotherapy (TNFi±GCs) and csDMARD-TNFi
combination therapy (TNFi+csDMARDs±GCs). csDMARDs
were defined as sulfasalazine, leflunomide, hydroxychloroquine or methotrexate in patients with RA, PsA and AS
and cyclosporine in patients with PsA. For AS only, additional categories were also defined because NSAIDs are a
cornerstone of treatment in this IMID:22–24 NSAID monotherapy (NSAIDs±GCs), NSAID-csDMARD combination
(NSAIDs+csDMARDs±GCs) and NSAID-TNFi combination
(NSAIDs+TNFi±GCs). NSAIDs were not included as part
of the treatment categories for RA and PsA because they
are supportive therapies in these IMIDs but are not disease
modifying.
To compare patient-reported high adherence (MMAS-4©
score=4) to a particular medication among the three IMIDs,
a multivariable logistic regression model was constructed
with factors for IMID (RA, PsA or AS) and each possible
kind of treatment. It was possible to compare adherence
only to treatments that were evaluated in more than one
IMID, hence, NSAIDs were not modelled. To account for

2

Smolen JS, et al. RMD Open 2019;5:e000585. doi:10.1136/rmdopen-2017-000585

Inflammatory arthritis
within-patient correlations, a random-effects model was
used. The reference IMID was PsA, which bears clinical
resemblances to RA and AS, and the reference treatment
was TNFi monotherapy.
Attitudinal segmentation
The BMQ-Specific Necessity and Concerns subscale ratings
were analysed in four attitudinal segments, similar to
the analysis by Aikens et al.25 On a scale from 5 to 25,
the attitudinal segments were defined as: accepting, with
BMQ-Specific Necessity score ≥15 and BMQ-Specific Concerns
score <15; ambivalent, with both scores ≥15; indifferent, with
both scores <15 and skeptical, with BMQ-Specific Necessity
score <15 and BMQ-Specific Concerns score ≥15.
Regression analysis of factors associated with medication
adherence
Potential associations of data from study assessments
with patient-reported high adherence were assessed by
multivariable logistic regression models. The full model
included factors for each study assessment. A further
exploratory analysis included full models plus the addition of fixed factors for geographic region. For combination therapy, separate ratings of adherence were
performed for each treatment component received by
the patient. To develop a final model, p value-based backward selection approaches (ie, removal of variables based
on p>0.05) were applied to eliminate extraneous factors
from the final adherence prediction regression models;
this approach automatically selected an adequate
complexity for the model based on the observed data.
Although backwards selection based on p values was used,
factors identifying treatment groups were always kept in
the models, regardless of statistical significance, as this
was important for the design of the analysis. Furthermore,
to account for potential within-patient correlations, the
final models were then refitted with a random-effects
logistic model with patient indicator as a random intercept. This final refitting procedure was conservative in its
treatment of predictors, so that only the most informative
variables were likely to remain significant.

knowledge), the variable with the largest p value. Then,
in stepwise fashion, it continued removing variables by
the same rule, stopping when all remaining variables had
p values less than the prespecified criterion (here, 0.05).
Therefore, the complexity (number of variables) in the
final model was determined automatically by the algorithm, without human intervention. Whenever feasible
while maintaining adequate predictive accuracy, the
models were simplified by dividing continuous factors
into dichotomous variables. The final model for each
rheumatic disease was the one with the highest predictive
accuracy, as estimated by 5-fold cross-validated area under
the receiver operating characteristic curve (AUROC)
while containing a substantial number of dichotomous
variables.
The second approach was conducted manually and
aimed to construct for each IMID (RA, PsA and AS) a
simplified 4-variable adherence prediction model with
good predictive power. In this less complex approach, the
choice of four variables balanced practical clinical utility
against predictive power; furthermore, four variables can
be conveniently presented in a risk prediction matrix.
The final simplified model for each rheumatic disease
was the one with the highest cross-validated AUROC
while containing a substantial number of dichotomous
variables. A visual representation of a typical patient
medication adherence probability profile for each of the
three final models (RA, PsA, and AS) from the second,
simplified approach was generated as a tabular matrix.
For both the 10-variable and 4-variable models, dichotomous variables were obtained from AUROC analysis.
Analyses were conducted with SAS V.9.2 and V.9.4.

Adherence prediction modelling
Two separate approaches were used to independently
develop two distinct models to predict medication adherence in patients with RA, PsA and AS. The first approach
was automated and aimed to construct, for each IMID
(RA, PsA and AS), a model with up to 10 variables with
the highest possible predictive power. In this more
complex approach, candidate models were developed
from the most important factors (based on ORs for risk
of non-adherence and practical considerations) for the
individual IMIDs in the multivariable regression analyses. The three reference models for RA, PsA and AS,
which had the greatest predictive power, comprised as
many continuous variables as possible. Beginning with a
full model, the backward selection algorithm removed,
based solely on statistical estimates (ie, without subjective

Results
Patients
Demographic and disease characteristics
A total of 3390 patients from ALIGN with rheumatic
IMIDs were analysed (RA, n=1943; PsA, n=635; AS,
n=812). As expected, the percentages of female
(highest in RA; lowest in AS) and white (highest in PsA)
patients varied significantly across the three rheumatic
conditions, as did patient age (lowest in AS). Race was
highly dependent on geographic region. The duration
of symptoms before diagnosis was shortest in RA and
longest in AS, but mean disease duration was 9–10 years
for all three evaluated diseases (table 1). Current but
not prior disease activity, both of which were defined
by the investigators, differed significantly among the
three rheumatic indications; moderate, moderate to
severe or severe current disease activity was reported
in 29.3%, 24.4% and 25.5% of patients with RA, PsA
and AS, respectively. The proportion of patients with >3
prior treatments varied significantly, with the highest
percentage in patients with RA. Response to current
treatments also differed significantly among the three
rheumatic IMIDs. A complete response (defined by
investigators) was reported in 47.5%, 52.8% and 57.4%
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Table 1 Patient demographic and disease characteristics, treatments and beliefs about medications
RA population
(n=1943)

PsA population
(n=635)

AS population
(n=812)

P Values

 Female, n (%)

1597 (82.2)

294 (46.3)

232 (28.6)

<0.0001

 White, n (%)*

1351 (70.0)

571 (90.1)

557 (68.8)

<0.0001

  Western Europe and Canada

892 (95.5)

443 (98.9)

399 (94.3)

  Eastern Europe and Middle East

360 (83.5)

96 (96.0)

140 (98.6)

  Latin America

31 (8.4)

7 (14.0)

1 (2.4)

  Asia Pacific

68 (32.2)

25 (67.6)

17 (8.3)

 Age, mean±SD (median), years†

54.8±13.5 (56.0)

50.7±12.4 (51.0)

42.5±12.4 (42.0)

<0.001

 Duration of formal education, mean±SD (median),
years‡

11.5±4.6 (12.0)

12.3±4.1 (12.0)

13.0±3.9 (13.0)

<0.001

Characteristic
Sociodemographic parameters

Duration of symptoms before diagnosis, years§

<0.0001

 <1

1042 (53.9)

257 (40.5)

216 (26.6)

 1–3

530 (27.4)

187 (29.5)

181 (22.3)

 >3

362 (18.7)

190 (30.0)

414 (51.0)

Duration of disease, mean±SD (median), years†

9.2±8.8 (6.3)

9.9±9.5 (7.0)

9.3±8.9 (6.1)

Current disease activity, n (%)¶,**

0.248 (RA vs PsA)
0.881 (RA vs AS)
0.379 (PsA vs AS)
0.0194

 Mild or mild to moderate disease

1371 (70.7)

480 (75.6)

604 (74.5)

 ≥Moderate disease

569 (29.3)

155 (24.4)

207 (25.5)

Prior disease activity, n (%)**,††

0.277

 Mild or mild to moderate disease

318 (16.5)

91 (14.3)

117 (14.6)

 ≥Moderate disease

1611 (83.5)

544 (85.7)

686 (85.4)

>3 prior treatments, n (%)

389 (20.0)

92 (14.5)

125 (15.4)

0.0007

Prior TNFi therapy, n (%)

598 (30.8)

253 (39.8)

411 (50.6)

<0.0001

 Complete response

921 (47.5)

335 (52.8)

463 (57.4)

 Partial response

941 (48.5)

270 (42.6)

310 (38.2)

 No response

57 (2.9)

13 (2.1)

25 (3.1)

Duration of current treatment, mean±SD (median), years

5.3±5.3 (3.6)

4.1±4.5 (2.9)

3.8±4.3 (2.6)

Response to current treatment, n (%)**,‡‡

<0.001

Patients currently taking IMID-related drugs by category,
n (%)

<0.001 (RA vs PsA and
AS)
0.263 (PsA vs AS)
NA

 csDMARD-TNFi combination

640 (32.9)

200 (31.5)

151 (18.6)

 NSAID-TNFi combination

NA

NA

123 (15.1)

 TNFi monotherapy

175 (9.0)

216 (34.0)

374 (46.1)

 NSAID-csDMARD combination

NA

NA

60 (7.4)

 csDMARD monotherapy

1128 (58.1)

219 (34.5)

25 (3.1)

 NSAID monotherapy

NA

NA

79 (9.7)

 TNFi

815 (41.9)

416 (65.5)

648 (79.8)

 Methotrexate

1399 (72.0)

343 (54.0)

116 (14.3)

 NSAID

NA

NA

310 (38.2)

 GC

658 (33.9)

51 (8.0)

51 (6.3)

 Hydroxychloroquine

348 (17.9)

9 (1.4)

1 (0.1)

 Leflunomide

288 (14.8)

50 (7.9)

6 (0.7)

 Aminosalicylate§§

149 (7.7)

44 (6.9)

123 (15.1)

Patients currently taking IMID-related drugs, n (%)

NA

Continued
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Table 1 Continued
Characteristic

RA population
(n=1943)

PsA population
(n=635)

AS population
(n=812)

 ≥1 other drug¶¶

27 (1.4)

12 (1.9)

5 (0.6)

 1—Consequences

5.3±2.9 (5.0)

5.3±2.8 (5.0)

5.5±2.8 (5.0)

0.870 (RA vs PsA)
0.275 (RA vs AS)
0.459 (PsA vs AS)

 2—Timeline

8.7±2.3 (10.0)

8.9±2.1 (10.0)

8.5±2.3 (10.0)

0.100 (RA vs PsA)
0.003 (RA vs AS)
<0.001 (PsA vs AS)

 8—Emotional Representation

5.3±3.1 (5.0)

5.4±3.1 (6.0)

5.2±3.0 (5.0)

0.301 (RA vs PsA)
0.608 (RA vs AS)
0.194 (PsA vs AS)

  
Necessity

19.8±3.4 (20.0)

19.6±3.5 (20.0)

18.9±3.8 (20.0)

0.112 (RA vs PsA)
<0.001 (RA vs AS)
0.001 (PsA vs AS)

  
Concerns

14.7±3.9 (15.0)

14.0±3.9 (14.0)

14.2±3.9 (14.0)

<0.001 (RA vs PsA and
AS)
0.261 (PsA vs AS)

BMQ-General Harm score; 4–20, mean±SD (median)†††

10.0±3.0 (10.0)

9.9±3.0 (10.0)

9.5±2.7 (9.0)

0.301 (RA vs PsA)
<0.001 (RA vs AS)
0.016 (PsA vs AS)

P Values

BIPQ item score; 0–10 for each component, mean±SD
(median)***

BMQ-Specific score; 5–25 for each component, mean±SD
(median)

Treatments: csDMARD monotherapy=csDMARDs±GCs; csDMARD-TNFi combination=TNFi +csDMARDs±NSAIDs±GCs; NSAID
monotherapy=NSAIDs±GCs; NSAID-csDMARD combination=csDMARDs +NSAIDs±GCs; NSAID-TNFi combination=TNFi +NSAIDs±GCs;TNFi
monotherapy=TNFi±GCs.
P values were from a Wilcoxon (continuous variables) or Pearson chi-square (categorical variables) test.
*Data missing for 16 patients (RA, n=13; PsA, n=1; AS, n=2).
†Data missing for 7 patients (RA, n=6; PsA, n=1).
‡Data missing for 117 patients (RA, n=64; PsA, n=22; AS, n=31).
§Data missing for 11 patients (RA, n=9; PsA, n=1; AS, n=1).
¶Data missing for 4 patients (RA, n=3; AS, n=1).
**Assessed by treating physician; prior and current disease activity was evaluated using a 5-point rating scale (ie, mild, mild to moderate, moderate,
moderate to severe, severe), and treatment response was categorised as ‘complete response’, ‘partial response’, ‘no response’ or ‘not evaluable’.
††Data missing for 23 patients (RA, n=14; AS, n=9).
‡‡Data missing for 10 patients (RA, n=3; PsA, n=1; AS, n=6) and not evaluable for 45 patients (1.3%; RA, n=21 (1.1%); PsA, n=16 (2.5%); AS, n=8
(1.0%)).
§§Includes sulfasalazine and mesalazine.
¶¶Includes gold compounds, azathioprine/6-mercaptopurine, cyclosporine and tacrolimus.
***Data missing for 75 patients (RA, n=42; PsA, n=16; AS, n=17).
†††Data missing for 35 patients (RA, n=22; PsA, n=8; AS, n=4).
AS, ankylosing spondylitis; BIPQ, Brief Illness Perception Questionnaire; GC, glucocorticoid; IMID, immune-mediated inflammatory disease;
MMAS-4©, 4-item Morisky Medication Adherence Scale; NA, not applicable; NSAID, non-steroidal anti-inflammatory drug; PsA, psoriatic arthritis;
RA, rheumatoid arthritis; TNFi, tumour necrosis factor inhibitor; csDMARD, conventional synthetic disease-modifying antirheumatic drug.

of patients with RA, PsA and AS, respectively; a ‘partial’
response was reported in 48.5%, 42.6% and 38.2% of
patients with RA, PsA and AS; and a ‘no’ response was
reported in 2.9%, 2.1% and 3.1% of patients with RA,
PsA and AS.
Treatment characteristics
Patients with RA had a significantly longer mean duration of current treatment (5.3 years) compared with
patients with PsA and AS (4.1 and 3.8 years, respectively). Among patients with RA, the largest proportion
(58.1%) received csDMARD therapy (±GC), whereas in
patients with AS, the largest proportion were receiving
TNFi monotherapy (46.1%). In patients with PsA,
approximately one-third were receiving csDMARD
Smolen JS, et al. RMD Open 2019;5:e000585. doi:10.1136/rmdopen-2017-000585

therapy, one-third TNFi monotherapy and one-third
csDMARD-TNFi combination therapy (table 1). The
most frequently used current systemic compounds were
methotrexate (±other therapies) in patients with RA
(72.0%) and TNFis (±other therapies) in patients with
PsA (65.5%) and AS (79.8%).
BIPQ and BMQ-specific findings
Of BIPQ items used in subsequent analyses, only Timeline (ie, perception of continuing length of illness)
differed significantly (highest in PsA, lowest in AS)
among the three rheumatic disease groups. Patients
with AS had a significantly lower BMQ-Specific Necessity
score compared with patients with RA and PsA; patients
5
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with RA had a significantly higher mean BMQ-Specific
Concerns score compared with patients with PsA and AS.
Medication adherence and attitudes
High adherence (MMAS-4© score=4) to a given treatment was similar among patients with RA (OR, 1.106;
95% CI 0.763 to 1.605 and PsA (reference group; OR=1)
but significantly lower in patients with AS (OR, 0.424;
95% CI 0.263 to 0.685). The percentage of patients
with high adherence also appeared to differ between
treatment regimens (figure 1), although no statistical
testing was performed because the multivariate regression analyses allowed adjustment for confounding
factors. Depending on the treatment, the percentage
of patients with high adherence was 57.3%–76.3%,
57.7%–70.4% and 28.2%–70.6% in patients with RA,
PsA and AS, respectively. Generally, a larger proportion of patients reported high adherence to TNFis with
or without concomitant csDMARDs compared with
csDMARDs and NSAIDs (AS). BMQ attitudinal segmentation revealed that large proportions of patients in
every rheumatic IMID group were accepting (high
treatment necessity beliefs/low concerns; 44.3%–49.4%
of patients) towards their medications (online supplementary figure 1). However, 41.9%–47.3% of patients
were ambivalent (high treatment necessity beliefs/high
concerns) towards their medications. Few patients were
indifferent (low necessity beliefs/low concerns) or
sceptical (low necessity beliefs/high concerns).
Factors affecting medication adherence
Current treatment type
The full starting models for multivariable regression
analyses of treatment adherence, before backwards
elimination of factors, are shown in online supplementary figure 2. In multivariable regression analysis,
several types of treatment had a positive association
with treatment adherence in RA and AS, although not
in PsA (table 2). TNFis with or without csDMARDs
had the most significantly greater ORs for adherence
compared with csDMARD monotherapy in patients
with RA (range, 3.63–5.45) and compared with NSAID
monotherapy in patients with AS (range, 6.33–22.69).
csDMARDs within csDMARD-TNFi combination
therapy were significantly associated with greater
adherence compared with csDMARD monotherapy
in patients with RA (OR, 2.09). NSAIDs as part of any
combination therapy in patients with AS were not associated with significantly greater adherence compared
with NSAID monotherapy.
Other factors
In multivariable regression analysis, older age (all three
IMIDs) and white race (RA and AS) were significantly associated with better treatment adherence, but sex was not
significantly associated with adherence in any of the three
rheumatic IMIDs (table 2). Illness perception (higher
BIPQ Emotional Representation scores, indicating greater
6

emotional impact) was significantly associated with worse
treatment adherence in patients with AS only. None of
the disease-related and medication-related factors, such as
disease activity or disease duration, were consistently associated with medication adherence across the three rheumatic
diseases. Having >3 pretreatments was significantly associated with worse medication adherence only in patients
with AS. In patients with PsA, longer duration of current
treatment was significantly associated with worse medication adherence, whereas complete treatment response
was significantly associated with better adherence. Across
all three indications, higher BMQ-Specific Necessity beliefs
were associated with higher treatment adherence, whereas
higher BMQ-Specific Concerns in patients with RA and
higher BMQ-General Harm beliefs in patients with RA and
PsA were significantly associated with poorer adherence.
Because race was highly dependent on geographic
region, further analyses explored adherence models in
which both race and geographic region were included as
factors. In these models, geographic region was treated
as a fixed variable because geographic categorisation
was part of the study design. The full starting models
for multivariable regression analyses of treatment adherence, before backwards elimination of factors, are shown
in online supplementary figure 3. In multivariable regression analysis (online supplementary table 1), the pattern
and magnitude of factors in relation to adherence were
mostly similar to the findings from the models without
geographic region (table 2). However, in the multivariable model with geographic factors, race was no longer
significant and was automatically removed from the
model (online supplementary table 1).
Predictive adherence models
Full models (up to 10 variables)
Three variables were shared across the full adherence
prediction models for RA, PsA and AS: type of treatment, age and medication beliefs (BMQ-Specific Necessity score). In patients with RA, the best full adherence
prediction model (AUROC, 0.68) included five variables besides the common ones: race, medication beliefs
(BMQ-Specific Concerns and BMQ-General Harm scores),
illness perception (score for BIPQ item 2 (Timeline)
with regard to continuing length of illness) and disease
duration (online supplementary table 2). In patients with
PsA, the best full model (AUROC, 0.68) included three
variables besides the common ones: medication beliefs
(BMQ-General Harm score), duration of current treatment and complete treatment response. In patients with
AS, the best full model (AUROC, 0.74) included three
variables besides the common ones: race, illness perception (score for BIPQ item 7 (Coherence) regarding
understanding of the disease), and number of prior
treatments.
Simplified models (four variables)
Two variables were included in each simplified adherence
prediction model for RA, PsA and AS: type of treatment
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Figure 1 Patient-reported adherence towards different IMID treatments in RA (A), PsA (B) or AS (C). Adherence
was defined as a binary variable with levels ‘highly adherent’ (MMAS-4©=4) and ‘not highly adherent’ (MMAS-4©<4).
Treatments: csDMARD mono=csDMARDs±GCs; csDMARD-NSAID combination=csDMARDs+NSAIDs±GCs; NSAID
mono=NSAIDs±GCs; TNFi mono=TNFi±GCs; TNFi-csDMARD combination=TNFi+csDMARDs±NSAIDs±GCs; TNFiNSAID combination=TNFi+NSAIDs±GCs. AS, ankylosing spondylitis; csDMARD, conventional synthetic disease-modifying
antirheumatic drug; GC, glucocorticoid; IMID, immune-mediated inflammatory disease; MMAS-4©, 4-item Morisky Medication
Adherence Scale; mono, monotherapy; NSAID, non-steroidal anti-inflammatory drug; PsA, psoriatic arthritis; RA, rheumatoid
arthritis; TNFi, tumour necrosis factor inhibitor.
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Table 2 Multivariable logistic regression analysis of treatments and other factors associated with medication adherence*
Parameter (retained based on
backward selection)

Component
being rated

OR (95% CI)†
RA population

PsA population

AS population

Treatment
 csDMARD-TNFi combination

TNFi

5.45 (3.35 to 8.87)‡

1.22 (0.54 to 2.75)

22.69 (6.34 to 81.21)‡

 NSAID-TNFi combination

TNFi

NA

NA

6.33 (1.84 to 21.84)‡

 TNFi monotherapy

TNFi

3.63 (1.72 to 7.69)‡

1.23 (0.55 to 2.73)

13.10 (4.27 to 40.18)‡

 csDMARD monotherapy

csDMARD

Reference

Reference

1.27 (0.20 to 7.86)

 csDMARD-TNFi combination

csDMARD

2.09 (1.35 to 3.25)‡

0.50 (0.22 to 1.10)

3.23 (0.99 to 10.58)

 NSAID-csDMARD combination

csDMARD

NA

NA

1.19 (0.28 to 5.08)

 csDMARD-TNFi combination

NSAID

NA

NA

1.69 (0.38 to 7.57)

 NSAID-TNFi combination

NSAID

NA

NA

1.15 (0.33 to 4.04)

 NSAID-csDMARD combination

NSAID

NA

NA

1.19 (0.28 to 5.08)

 Age, years

1.05 (1.03 to 1.06)‡

1.07 (1.04 to 1.11)‡

1.03 (1.01 to 1.06)‡

 Race (white vs other)

2.25 (1.51 to 3.36)‡

―

3.10 (1.66 to 5.78)‡

 Sex (female vs male)

―

―

1.73 (0.96 to 3.12)

 BIPQ item 1—Consequences

―

―

1.10 (0.99 to 1.23)

 BIPQ item 2—Timeline

1.08 (1.00 to 1.17)

―

―

 BIPQ item 8–Emotional
Representation

―

―

0.86 (0.77 to 0.95)‡

 Disease duration, years

0.97 (0.95 to 0.99)‡

―

―

 Number of pretreatments (>3 vs
≤3)

―

―

0.34 (0.16 to 0.72)‡

 Duration of current treatment,
years

―

0.91 (0.85 to 0.97)‡

―

 Treatment response (complete vs
non-complete)§

―

2.19 (1.17 to 4.09)‡

―

 BMQ-Specific Necessity

1.12 (1.07 to 1.18)‡

1.13 (1.04 to 1.23)‡

1.18 (1.09 to 1.28)‡

 BMQ-Specific Concerns

0.92 (0.87 to 0.97)‡

―

―

 BMQ-General Harm

0.88 (0.83 to 0.95)‡

0.85 (0.77 to 0.94)‡

―

Sociodemographic factors

Illness perception

Disease-/medication-related factors

Beliefs factors

― = eliminated from model; NA=not applicable (NSAIDs were only taken by patients with AS; therefore there are no data for NSAID-containing
regimens for patients with RA and PsA).
*Adherence was defined as a binary variable: highly adherent (MMAS-4© score=4) or not highly adherent (MMAS-4© score <4).
†Except where noted, ORs represent the impact of treatment vs reference (csDMARD in csDMARD monotherapy for RA and PsA; NSAID
monotherapy for AS) or the impact of a 1-unit or 1 year increase (other factors); empty cells denote that a variable was not selected in the regression
model for the respective indication.
‡P<0.05 vs OR of 1.
§Determined by treating physician; treatment response was categorised as ‘complete response’, ‘partial response’, ‘no response’ or ‘not evaluable’.
AS, ankylosing spondylitis; BIPQ, Brief Illness Perception Questionnaire; BMQ, Beliefs about Medicines Questionnaire; GC, glucocorticoid; IMID,
immune-mediated inflammatory disease; MMAS-4©, 4-item Morisky Medication Adherence Scale; NA, not applicable; NSAID, non-steroidal antiinflammatory drug; OR, odds ratio; PsA, psoriatic arthritis; RA, rheumatoid arthritis; TNFi, tumour necrosis factor inhibitor; csDMARD, conventional
synthetic disease-modifying antirheumatic drug.

and age. In patients with RA, the best simplified adherence prediction model (AUROC, 0.64) included two
variables besides the common ones: race and medication
beliefs (BMQ-General Harm score (online supplementary table 2). In patients with PsA, the best simplified
model (AUROC, 0.64) included two variables besides
the common ones: medication beliefs (BMQ-General
Harm score) and duration of disease. In patients with AS,
the best simplified model (AUROC, 0.72) included two

variables besides the common ones: race and medication
beliefs (BMQ-Specific Concerns score).
Predicted probabilities of high adherence in the simplified models ranged widely (RA, 28.6%–96.2% (table 3);
PsA, 21.7%–95.5% (table 4); AS, 5.0%–94.1% (table 5)).
According to the simplified models, the highest predicted
probability of high adherence was to TNFi treatment
(especially in combination with csDMARDs; tables 3–5).
In patients with RA and PsA, higher adherence was
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Table 3

Predicted probability of high adherence to maintenance treatments per posthoc simplified rheumatoid arthritis model
Predicted high adherence* probability (% (95% CI)) in patients with RA (n=1943)
White patients

Non-white patients

Low BMQ-General
Harm Score (<11)

High BMQ-General
Harm Score (≥11)

Low BMQ-General
Harm Score (<11)

High BMQ-General
Harm Score (≥11)

 csDMARD-TNFi combination TNFi

96.2 (93.8 to 97.7)

92.3 (87.9 to 95.2)

91.0 (85.5 to 94.5)

82.6 (74.0 to 88.8)

 TNFi monotherapy

Treatment†‡

Component
being rated

Age ≥58 years
94.5 (89.6 to 97.2)

89.0 (80.5 to 94.1)

87.2 (77.0 to 93.3)

76.3 (61.5 to 86.6)

 csDMARD-TNFi combination csDMARD

TNFi

90.8 (86.4 to 93.9)

82.3 (75.1 to 87.7)

79.6 (70.8 to 86.2)

64.7 (53.5 to 74.6)

 csDMARD monotherapy

84.9 (79.6 to 89.0)

72.6 (65.0 to 79.0)

69.0 (59.6 to 77.0)

51.1 (41.2 to 61.0)

 csDMARD-TNFi combination TNFi

90.7 (86.1 to 93.9)

82.1 (74.6 to 87.8)

79.4 (71.0 to 85.8)

64.5 (53.8 to 74.0)

 TNFi monotherapy

csDMARD

Age <58 years
86.8 (77.6 to 92.6)

75.7 (62.1 to 85.5)

72.3 (57.6 to 83.4)

55.2 (39.0 to 70.3)

 csDMARD-TNFi combination csDMARD

TNFi

79.0 (71.9 to 84.7)

64.0 (54.2 to 72.7)

59.8 (49.7 to 69.2)

41.3 (31.3 to 51.9)

 csDMARD monotherapy

68.2 (60.8 to 74.8)

50.3 (41.7 to 58.9)

45.9 (37.3 to 54.9)

28.6 (21.5 to 36.9)

csDMARD

*High/full medication adherence: 4-item Morisky Medication Adherence Scale©=4.
†With or without concomitant glucocorticoid.
‡Some combinations are not recommended according to the American College of Rheumatology and European League Against Rheumatism.39 40
BMQ, Beliefs about Medicines Questionnaire; RA, rheumatoid arthritis; TNFi, tumour necrosis factor inhibitor; csDMARD, conventional synthetic
disease-modifying antirheumatic drug.

seen in older patients with low treatment harm beliefs;
in patients with AS, higher adherence was seen in older
patients with low treatment concerns. In patients with
RA and AS, the predicted probability of high adherence
was greater in white patients compared with non-white
patients who otherwise had the same characteristics;
in patients with PsA, the predicted probability of high
adherence was greater with duration of disease <9 years
compared with ≥9 years in patients who otherwise had
the same characteristics. Thus, for all three IMIDs, clinicians may wish to promote adherence in younger patients
and among those who either had concerns about their

specific medications or who believed that medications in
general cause harm, as a higher risk of low adherence was
found to be related to these factors. Similarly, it also may
be advisable to emphasise the importance of adherence
to patients with RA or AS who are not white and patients
with PsA of long duration.
Discussion
ALIGN was the first large cross-sectional study to
explore patients’ beliefs and treatment adherence to
systemic medication across six IMIDs, including three

Table 4 Predicted probability of high adherence to maintenance treatments per posthoc simplified psoriatic arthritis model
Predicted high adherence* probability (% (95% CI)) in patients with PsA (n=635)
Short disease duration (<9 years)

Long disease duration (≥9 years)

Component
being rated

Low BMQ-General
Harm Score (<12)

High BMQ-General
Harm Score (≥12)

Low BMQ-General
Harm Score (<12)

High BMQ-General
Harm Score (≥12)

 csDMARD-TNFi combination

TNFi

95.1 (88.8 to 98.0)

87.1 (74.7 to 93.9)

90.1 (80.5 to 95.3)

76.0 (59.2 to 87.4)

 TNFi monotherapy

TNFi

95.5 (89.4 to 98.2)

88.0 (75.8 to 94.5)

90.9 (81.8 to 95.6)

77.5 (61.3 to 88.2)

 csDMARD-TNFi combination

csDMARD

87.9 (77.0 to 94.1)

71.6 (54.3 to 84.3)

77.3 (62.8 to 87.3)

54.2 (36.0 to 71.3)

 csDMARD monotherapy

csDMARD

91.7 (83.7 to 96.0)

79.4 (64.4 to 89.1)

83.9 (71.3 to 91.6)

64.3 (45.1 to 79.9)

 csDMARD-TNFi combination

TNFi

82.1 (69.2 to 90.3)

61.4 (43.0 to 77.0)

68.3 (51.3 to 81.4)

42.7 (24.9 to 62.6)

 TNFi monotherapy

TNFi

83.3 (71.4 to 90.9)

63.3 (45.7 to 78.0)

70.0 (54.8 to 81.8)

44.7 (27.6 to 63.2)

 csDMARD-TNFi combination

csDMARD

63.1 (47.2 to 76.6)

37.2 (22.0 to 55.5)

44.5 (28.5 to 61.7)

21.7 (10.7 to 39.3)

 csDMARD monotherapy

csDMARD

72.3 (57.8 to 83.2)

47.5 (30.0 to 65.6)

55.0 (37.0 to 71.9)

29.8 (14.9 to 50.6)

Treatment†‡
Age ≥51 years

Age <51 years

©

*High/full medication adherence: 4-item Morisky Medication Adherence Scale =4.
†With or without concomitant glucocorticoid.
‡Some combinations are not recommended according to the European League Against Rheumatism.41
BMQ, Beliefs about Medicines Questionnaire; PsA, psoriatic arthritis; TNFi, tumour necrosis factor inhibitor; csDMARD, conventional synthetic
disease-modifying antirheumatic drug.
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Table 5 Predicted probability of high adherence to maintenance treatments per posthoc simplified ankylosing spondylitis
model
Predicted high adherence* probability (% (95% CI)) in patients with AS (n=812)
White patients

Non-white patients

Component
being rated

Low BMQ-Specific
Concerns Score
(<14)

High BMQ-Specific
Concerns Score
(≥14)

Low BMQ-Specific
Concerns Score
(<14)

High BMQ-Specific
Concerns Score
(≥14)

 csDMARD-TNFi combination

TNFi

94.1 (87.6 to 97.3)

90.5 (81.6 to 95.4)

82.2 (66.9 to 91.4)

73.4 (56.3 to 85.5)

 TNFi monotherapy

TNFi

90.2 (83.5 to 94.4)

84.6 (75.9 to 90.5)

72.6 (56.7 to 84.3)

61.2 (45.2 to 75.1)

 NSAID-TNFi combination

TNFi

82.7 (68.6 to 91.3)

74.0 (57.1 to 85.8)

57.9 (37.2 to 76.1)

45.0 (26.9 to 64.5)

 csDMARD-TNFi combination

Treatment†‡
Age ≥44 years

csDMARD

68.1 (51.5 to 81.1)

56.0 (39.3 to 71.4)

38.1 (21.8 to 57.5)

26.8 (14.8 to 43.6)

 NSAID-csDMARD combination csDMARD

52.8 (28.4 to 76.0)

40.0 (19.6 to 64.5)

24.4 (9.6 to 49.5)

16.1 (6.2 to 35.8)

 csDMARD monotherapy

csDMARD

46.7 (17.2 to 78.7)

34.2 (10.7 to 69.3)

20.1 (5.2 to 53.6)

13.0 (3.1 to 41.1)

 NSAID-TNFi combination

NSAID

44.5 (26.5 to 64.0)

32.3 (17.7 to 51.5)

18.7 (8.4 to 36.7)

12.1 (5.3 to 25.3)

 NSAID-csDMARD combination NSAID

45.8 (22.8 to 70.8)

33.5 (15.2 to 58.5)

19.6 (7.3 to 43.1)

12.7 (4.6 to 30.3)

 NSAID monotherapy

NSAID

48.7 (27.6 to 70.2)

36.1 (18.6 to 58.2)

21.4 (8.9 to 43.3)

14.0 (5.6 to 30.8)

 csDMARD-TNFi combination

TNFi

86.0 (73.6 to 93.1)

78.5 (63.1 to 88.7)

63.9 (45.2 to 79.1)

51.3 (34.1 to 68.1)

 TNFi monotherapy

TNFi

77.9 (67.3 to 85.7)

67.7 (55.4 to 77.9)

50.3 (35.5 to 65.0)

37.6 (25.4 to 51.6)

 NSAID-TNFi combination

TNFi

64.6 (46.6 to 79.2)

52.1 (34.3 to 69.4)

34.4 (19.7 to 53.0)

23.8 (13.0 to 39.6)

 csDMARD-TNFi combination

Age <44 years

csDMARD

44.9 (28.2 to 62.9)

32.7 (19.0 to 50.2)

19.0 (9.7 to 33.9)

12.3 (6.1 to 23.0)

 NSAID-csDMARD combination csDMARD

29.9 (12.7 to 55.6)

20.3 (8.1 to 42.3)

11.0 (3.8 to 27.4)

6.8 (2.4 to 17.9)

 csDMARD monotherapy

csDMARD

25.1 (7.2 to 59.2)

16.6 (4.2 to 47.3)

8.8 (2.0 to 30.8)

5.4 (1.2 to 21.4)

 NSAID-TNFi combination

NSAID

23.4 (12.0 to 40.8)

15.4 (7.3 to 29.6)

8.1 (3.4 to 17.9)

5.0 (2.1 to 11.5)

 NSAID-csDMARD combination NSAID

24.4 (9.8 to 49.1)

16.1 (6.1 to 36.4)

8.5 (2.9 to 22.7)

5.2 (1.8 to 14.6)

 NSAID monotherapy

26.6 (12.6 to 47.7)

17.7 (7.8 to 35.5)

9.4 (3.6 to 22.3)

5.8 (2.2 to 14.5)

NSAID

©

*High/full medication adherence: 4-item Morisky Medication Adherence Scale =4.
†With or without concomitant glucocorticoid.
‡Some combinations are not recommended according to the American College of Rheumatology, Assessment of Spondyloarthritis International
Society and the European League Against Rheumatism.22–24
AS, ankylosing spondylitis; BMQ, Beliefs about Medicines Questionnaire; NSAID, non-steroidal anti-inflammatory drug; TNFi, tumour necrosis factor
inhibitor; csDMARD, conventional synthetic disease-modifying antirheumatic drug.

rheumatological diseases. In all three evaluated rheumatic diseases (RA, PsA and AS), higher treatment
necessity beliefs were more consistently associated with
medication adherence than disease-related or medication-related factors. The direct positive relationship
of TNFi treatment with necessity beliefs in ALIGN16
appeared to be associated with higher medication
adherence in patients with RA and AS, although not
in patients with PsA. Models that used subsets of the
key factors had moderate ability to predict medication
adherence in patients with RA, PsA and AS. The adherence prediction models were developed via two distinct
approaches. The first approach used automated selection of variables to determine which of a large number of
potential factors produced models with a higher predictive performance. The second approach used a prognostic model with only one categorical predictor (treatment type) and three other dichotomized predictors;
although the simpler models had slightly less predictive
power than the models from the first approach, they
would be easier to integrate into clinical practice. In

applied psychology and prediction of future behaviour, AUROC values approximately >0.70 are considered strong effects.26 The predictive accuracy of our AS
adherence prediction model exceeded an AUROC of
0.70 and appeared to be of higher accuracy compared
with those of the RA and PsA models.
To our knowledge, our models are the first that have
been developed to estimate the probability of high
adherence to systemic therapies in patients with RA,
PsA and AS. Thus, no other adherence models are
available for comparison to determine the value of our
models. Adherence prediction models in other diseases
showed higher predictive accuracy.27–32 However, our
adherence prediction models cannot be compared
with those models because of differences in the aims of
the previously published models, their analysed patient
populations and diseases, the definitions and measurement of adherence and compliance and study design
(eg, longitudinal vs cross-sectional design; single-variable model vs multivariable model). The moderate
predictive accuracy of our models may be the result of
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unidentified factors that could affect adherence on an
individual level but which are not identifiable in a large
patient population. The degree of self-reported high
medication adherence varied widely among patients
with RA, PsA and AS in ALIGN, consistent with a systematic review of findings from other studies.6 The reason
for a higher observed adherence to TNFi’s compared
with other treatments in ALIGN cannot be explained
by the results of this study but could stem from a favourable balance between perceptions of treatment necessity versus concerns about adverse effects, which would
be in line with multiple reports that found a role for
such beliefs in affecting adherence.8 33–37 Because many,
and in some countries all, patients receiving TNFi’s or
other biological or targeted synthetic DMARDs are
enrolled in a registry (particularly in Europe), their
physicians or other healthcare providers will regularly monitor their disease in a structured manner;
this could also have a positive effect on adherence. In
addition to beliefs about treatments, factors that were
significantly associated with high medication adherence in ALIGN notably included greater age and white
race (the latter interrelated with geographic region).
Interestingly, disease-related factors were infrequently
associated with high adherence when the variables were
considered across the three different IMID groups. The
limited number of significant strong predictors did,
however, facilitate development of adherence prediction models with manageable numbers of components.
Each of the three final models shared type of treatment
and age as factors; however, not all treatments were
comparable among IMIDs, because NSAIDs (which are
considered disease modifying and cornerstone first-line
treatment in AS but not RA or PsA) were modelled only
for the AS population. Heterogeneity in the structures
of the three final models, perhaps deriving ultimately
from the dissimilar experiences of patients with RA,
PsA and AS, underscores the need for separate analysis
in each IMID to enable accurate prediction of medication adherence. Although in the present study separate
analyses were needed for the three conditions investigated because of different profiles, it would be desirable to have a single adherence prediction model for
all three diseases; based on the present study, it may be
possible to develop such a tool in the future.
Several limitations of ALIGN and the current analyses
should be noted. First, and perhaps most important,
the number of patients with RA was greater than the
numbers of patients with PsA and AS; consequently,
statistical power was dissimilar in the three groups. This
could have impaired detection of significant effects in
some analysis groups. Second, as expected from the
epidemiology of each condition, patients in the three
different rheumatic IMID populations differed in their
sociodemographic, disease and treatment characteristics. For example, a higher percentage of patients with
AS received TNFi compared with patients with RA and
PsA; this presumably was due to the general inefficacy

of csDMARDs and other biologics for treating AS.24
Therefore, it was impossible to pool data across rheumatic diseases or to produce an adherence prediction
model that would be applicable to all three conditions.
Third, the proportion of white patients within each
IMID group depended strongly on the geographic
region, and adherence as well as treatment patterns
may have been linked to country-specific factors,
such as restricted access to certain medications, and
cultural beliefs. The interdependence of race and
geographic region was confirmed by using models in
which geographic region was a fixed factor, resulting
in the automatic elimination of race as an independent
predictive factor. Fourth, disease activity was judged
subjectively by the investigators, rather than assessed
by some objective measure. Fifth, treatment adherence was based on patient self-reporting and was not
confirmed by objective measures. However, patients
completed and turned in the questionnaires in private
and anonymously so that they could answer honestly
without worries about censure. Nevertheless, some
other means to measure medication acquisition may
be helpful and, indeed, consistent with the results of
the present study. A recent study assessed adherence
to medications in patients with RA (n=178) using an
objective measure of adherence (medication possession ratio) and found that 89% of patients showed good
adherence to biological DMARDs.38 Sixth, by design,
the survey captured data from only a single point in
time; however, information was also collected on the
patients’ disease history. Finally, development of the
final adherence prediction models via AUROC analysis was a posthoc effort, although the identification of
individual predictive factors by multivariable regression
analysis was prospectively planned.
In conclusion, patients with rheumatic IMIDs who
participated in a large, multicountry patient survey
study exhibited treatment beliefs that were strongly
associated with adherence to systemic medications.
Among the treatment regimens that were examined,
adherence was highest for TNFis, whether as monotherapy or in combination with other agents. Simplified models that combined treatment beliefs with other
key significant predictive factors, such as age, race and
treatment duration, provided moderate power in estimating adherence to different systemic medications.
These models may be useful in tailoring interventions
to increase adherence in individual patients, as the
demographic predictors can indicate whom to target,
whereas the medication belief predictors indicate what
to target in an adherence support intervention. Tools
to facilitate use of these models in community rheumatology practice would allow application and further
validation in real-world populations. Because ALIGN
was the first large, cross-sectional study of its kind,
confirmatory research using more objective criteria is
needed.
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